May 2026
1. LUQUE MT, Du L, Rouzier V, Machado DM, et al
   Use of Integrase Strand Transfer Inhibitors Among Children Living With HIV in Latin America and the Caribbean.
   Pediatr Infect Dis J. 2026 May 22. doi: 10.1097/INF.0000000000005281.
   

   >> Share

   
   March 2026
2. NANTANEE R, Lolekha R, Lertpiriyasuwat C, Puangtaptim W, et al
   High Viral Suppression Rates and Attrition Rates Among Children With Perinatally Acquired HIV in the Thai National AIDS Program, 2023.
   Pediatr Infect Dis J. 2026;45:251-257.
   

   >> Share

   
   February 2026
3. NATUKUNDA E, Szubert AJ, Bwakura-Dangarembizi M, Mulenga V, et al
   Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial.
   Pediatr Infect Dis J. 2026 Feb 24. doi: 10.1097/INF.0000000000005195.
   

   >> Share

   
   January 2026
4. OZBAKIR H, Aksoy Y, Ergun D, Aksoy Timur S, et al
   Safety and Tolerability of Raltegravir in a Premature Neonate: A Case Report.
   Pediatr Infect Dis J. 2026 Jan 28. doi: 10.1097/INF.0000000000005160.
   

   >> Share

   
   December 2025
5. TORRE P 3RD, Sirag E, Williams PL, Zhang Z, et al
   Hearing Measures in Children Perinatally HIV-exposed and Uninfected in the PHACS SMARTT Study.
   Pediatr Infect Dis J. 2025 Dec 8. doi: 10.1097/INF.0000000000005098.
   

   >> Share

   
   July 2025
6. HAGENS L, Bevers LAH, Malaba TR, Nassiwa SC, et al
   The Effects on the Growth of HIV-exposed Uninfected Infants of Initiating Dolutegravir-based Versus Efavirenz-based cART in Late Pregnancy (DolPHIN-2).
   Pediatr Infect Dis J. 2025 Jul 18. doi: 10.1097/INF.0000000000004902.
   

   >> Share

   
   May 2025
7. RABIE H, Yin DE, Ward S, Rani Y, et al
   Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results.
   Pediatr Infect Dis J. 2025 May 23. doi: 10.1097/INF.0000000000004859.
   

   >> Share

   
   
8. WACHARACHAISURAPOL N, Rungsapphaiboon A, Anugulruengkitt S, Sirikutt P, et al
   Pharmacokinetics of Generic Pediatric Abacavir/Lamivudine Dispersible Tablets in Thai Young Children Living With HIV Weighing Below Twenty Kilograms.
   Pediatr Infect Dis J. 2025;44:428-430.
   

   >> Share

   
   April 2025
9. ANTWI S, Enimil A, Yang H, Martyn-Dickens C, et al
   Pharmacokinetics of Tenofovir Diphosphate, Lamivudine Triphosphate and Emtricitabine Triphosphate in Adolescents With HIV Infection With and Without Tuberculosis Coinfection.
   Pediatr Infect Dis J. 2025 Apr 10. doi: 10.1097/INF.0000000000004831.
   

   >> Share

   
   March 2025
10. LEE P, Lee KE, Anosike BI
    Evolving COVID-19 Landscape: Assessing the Effectiveness and Safety Profile of Nirmatrelvir/Ritonavir in Adolescents.
    Pediatr Infect Dis J. 2025;44:e81-e84.
    

    >> Share

    
    January 2025
11. WACHARACHAISURAPOL N, Rungsapphaiboon A, Anugulruengkitt S, Sirikutt P, et al
    Pharmacokinetics of Generic Pediatric Abacavir/Lamivudine Dispersible Tablets in Thai Young Children Living With HIV Weighing Below Twenty Kilograms.
    Pediatr Infect Dis J. 2025 Jan 10. doi: 10.1097/INF.0000000000004683.
    

    >> Share

    
    December 2024
12. BERNARDI S, Roversi M, Torelli A, Musolino A, et al
    Safety of Nirmatrelvir-Ritonavir Administration in Children With Immunodeficiency and/or Comorbidities With SARS-CoV-2 Infection: A Retrospective Clinical Report.
    Pediatr Infect Dis J. 2024 Dec 27. doi: 10.1097/INF.0000000000004657.
    

    >> Share

    
    March 2024
13. GREYBE L, Barnabas S, Cotton M, Rose P, et al
    Cardiometabolic Risk Profiles of Adolescents Living With Perinatally Acquired HIV in South Africa.
    Pediatr Infect Dis J. 2024 Mar 26. doi: 10.1097/INF.0000000000004340.
    

    >> Share

    
    February 2024
14. KENNEALLY AM, Bates BN
    Accidental Raltegravir Overdose in a Neonate: Case Report and Review of Literature.
    Pediatr Infect Dis J. 2024 Feb 6. doi: 10.1097/INF.0000000000004273.
    

    >> Share

    
    January 2024
15. BEKKER A, Yang J, Wang J, Cotton MF, et al
    Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age.
    Pediatr Infect Dis J. 2024 Jan 4. doi: 10.1097/INF.0000000000004243.
    

    >> Share

    
    November 2023
16. EPALZA C, Valades-Alcaraz A, Gonzalez-Alba JM, Beltran-Pavez C, et al
    Transmitted Drug Resistance and HIV Diversity Among Adolescents Newly Diagnosed With HIV in Spain.
    Pediatr Infect Dis J. 2023 Nov 3. doi: 10.1097/INF.0000000000004138.
    

    >> Share

    
    July 2023
17. CHABALA C, Turkova A, Kapasa M, LeBeau K, et al
    Inadequate Lopinavir Concentrations With Modified 8-hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV.
    Pediatr Infect Dis J. 2023 Jul 20. doi: 10.1097/INF.0000000000004047.
    

    >> Share

    
    May 2023
18. NAKIDDU NJ, Bakeera-Kitaka S, Musoke P
    Prevalence and Factors Associated With Delayed Puberty Among Adolescents on Boosted Protease Inhibitor-based Second-line Antiretroviral Therapy: A Cross-sectional Study at a Pediatric Infectious Diseases Clinic in Uganda.
    Pediatr Infect Dis J. 2023;42:407-411.
    

    >> Share

    
    March 2023
19. DENOEUD-NDAM L, Stecker C, Andifasi P, Mushavi A, et al
    Implementation and Uptake of Raltegravir Granules in Newborns Diagnosed With HIV Through Birth Testing in Maternity Settings in Zimbabwe During the COVID-19 Pandemic.
    Pediatr Infect Dis J. 2023 Mar 20. doi: 10.1097/INF.0000000000003906.
    

    >> Share

    
    February 2023
20. BACHA JM, Dlamini S, Anabwani F, Gwimile J, et al
    Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa.
    Pediatr Infect Dis J. 2023 Feb 14. doi: 10.1097/INF.0000000000003878.
    

    >> Share

    
    
21. DODI I, Romanini E, Veronese P, Cangelosi AM, et al
    Highly Active Antiretroviral Therapy in an Extremely Low Birth Weight Newborn With in Utero Transmission of HIV.
    Pediatr Infect Dis J. 2023 Feb 8. doi: 10.1097/INF.0000000000003857.
    

    >> Share

    
    October 2022
22. WANG L, Kourtis AP, Wiener J, Chen L, et al
    Impact of Tenofovir Disoproxil Fumarate Use During Pregnancy on Maternal Bone Mineral Density.
    Pediatr Infect Dis J. 2022 Oct 11. pii: 00006454-990000000-00212.
    

    >> Share

    
    August 2022
23. LIYANAGE M, Nikanjam M, McFadyen L, Vourvahis M, et al
    Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life.
    Pediatr Infect Dis J. 2022 Aug 9. pii: 00006454-990000000-00156.
    

    >> Share

    
    July 2022
24. STEEGEN K, Levin L, Evans D, Technau KG, et al
    Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment.
    Pediatr Infect Dis J. 2022 Jul 20. pii: 00006454-990000000-00138.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share